Maxwell Skor
Stock Analyst at Morgan Stanley
(2.30)
# 2,673
Out of 5,245 analysts
7
Total ratings
33.33%
Success rate
22.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Initiates: Overweight | $115 | $63.12 | +82.19% | 1 | Jan 9, 2026 | |
| INSM Insmed | Maintains: Equal-Weight | $126 → $144 | $106.24 | +35.54% | 1 | Aug 21, 2025 | |
| ASND Ascendis Pharma | Assumes: Overweight | $250 | $247.05 | +1.19% | 1 | Jul 3, 2025 | |
| SANA Sana Biotechnology | Assumes: Overweight | $12 | $3.07 | +290.88% | 1 | Jul 3, 2025 | |
| TCRX TScan Therapeutics | Assumes: Overweight | $10 | $1.06 | +843.40% | 1 | Mar 14, 2025 | |
| IVVD Invivyd | Maintains: Overweight | $9.5 → $3.55 | $1.10 | +222.73% | 2 | Nov 20, 2024 |
Monopar Therapeutics
Jan 9, 2026
Initiates: Overweight
Price Target: $115
Current: $63.12
Upside: +82.19%
Insmed
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $126 → $144
Current: $106.24
Upside: +35.54%
Ascendis Pharma
Jul 3, 2025
Assumes: Overweight
Price Target: $250
Current: $247.05
Upside: +1.19%
Sana Biotechnology
Jul 3, 2025
Assumes: Overweight
Price Target: $12
Current: $3.07
Upside: +290.88%
TScan Therapeutics
Mar 14, 2025
Assumes: Overweight
Price Target: $10
Current: $1.06
Upside: +843.40%
Invivyd
Nov 20, 2024
Maintains: Overweight
Price Target: $9.5 → $3.55
Current: $1.10
Upside: +222.73%